In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 151 to 160 of 375

Sort by

Type: Guidance`Remove $Type: Guidance filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]	Technology appraisal guidance	TBC
Implanting a baroreceptor stimulation device for resistant hypertension	Interventional procedures guidance	TBC
Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]	Technology appraisal guidance	TBC
In-situ normothermic regional perfusion of the abdomen for livers donated after controlled circulatory death	Interventional procedures guidance	19 November 2026
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]	Technology appraisal guidance	TBC
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]	Technology appraisal guidance	TBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]	Technology appraisal guidance	TBC
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]	Technology appraisal guidance	21 May 2026
Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]	Technology appraisal guidance	TBC
Insulin efsitora alfa for treating type 2 diabetes [ID6499]	Technology appraisal guidance	22 October 2026

Results per page

10
25
50
All